IP Library Granted Patent US 12,319,718
Granted Patent B2
US 12,319,718 · App. 17/421,243 · Granted Jun 3, 2025

Modified fibroin

Inventors: Keisuke Morita (Tsuruoka, JP); Yunosuke Abe (Tsuruoka, JP); Hiroyuki Nakamura (Tsuruoka, JP); Shota Togashi (Tsuruoka, JP); Tetsuo Asakura (Fuchu, JP)
Assignee: Spiber Inc.
C07K14/43586C12N15/63C12P21/02D01F4/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,319,718
App. No.
17/421,243
Granted
Jun 3, 2025
Kind
B2
Abstract

The present invention relates to a modified fibroin including a domain sequence represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m -(A) n motif, and having a serine residue content rate of less than 5.5%. [In Formula 1 and Formula 2, the (A) n motif represents an amino acid sequence consisting of 4 to 27 amino acid residues, and the number of alanine residues with respect to the total number of amino acid residues in the (A) n motif is 80% or more. REP represents an amino acid sequence consisting of 10 to 200 amino acid residues. m represents an integer of 10 to 300. The plurality of (A) n motifs may be the same amino acid sequence or different amino acid sequences. A plurality of REPs may be the same amino acid sequence or different amino acid sequences.]

Claims (31)

1. A modified fibroin comprising a domain sequence represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m -(A) n motif, wherein a serine residue content rate is less than 5.5%, and wherein:

in Formula 1 and Formula 2, the (A) n motif represents an amino acid sequence consisting of 4 to 27 amino acid residues and the number of alanine residues with respect to the total number of amino acid residues in the (A) n motif is 80% or more, REP represents an amino acid sequence consisting of 10 to 200 amino acid residues, m represents an integer of 10 to 300, the plurality of (A) n motifs may be the same amino acid sequence or different amino acid sequences, and the plurality of REPs may be the same amino acid sequence or different amino acid sequences.

2. The modified fibroin according to claim 1 , wherein a threonine residue content rate is 9% or less.

3. The modified fibroin according to claim 1 , wherein a content rate of serine residue and threonine residue is 9% or less.

4. The modified fibroin according to claim 1 , wherein the modified fibroin comprises: an amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 28; or an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 28.

5. The modified fibroin according to claim 1 , further comprising a tag sequence at either or both of an N-terminal and a C-terminal.

6. The modified fibroin according to claim 5 , wherein the tag sequence includes an amino acid sequence set forth in SEQ ID NO: 17 or SEQ ID NO: 18.

7. The modified fibroin according to claim 1 , wherein the modified fibroin comprises: an amino acid sequence set forth in SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 25; or an amino acid sequence having 90% or more sequence identity with the amino acid sequence set forth in SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 25.

8. A nucleic acid encoding the modified fibroin according to claim 1 .

9. A nucleic acid hybridizing with a complementary strand of the nucleic acid according to claim 8 under hybridization conditions, wherein there is at least 85% or more identity between the sequences, and include at 42° C. using 5×SSC containing 0.5% SDS, and encoding a modified fibroin including a domain sequence represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A)˜motif-REP]m-(A) n motif, and wherein: in Formula 1 and Formula 2, the (A) n motif represents an amino acid sequence consisting of 4 to 27 amino acid residues and the number of alanine residues with respect to the total number of amino acid residues in the (A) n motif is 80% or more, REP represents an amino acid sequence consisting of 10 to 200 amino acid residues, m represents an integer of 10 to 300, the plurality of (A) n motifs may be the same amino acid sequence or different amino acid sequences, and the plurality of REPs may be the same amino acid sequence or different amino acid sequences.

10. A nucleic acid having 90% or more sequence identity with the nucleic acid according to claim 8 and encoding a modified fibroin including a domain sequence represented by Formula 1: [(A) n motif-REP] m or Formula 2: [(A) n motif-REP] m -(A) n motif, and wherein:

in Formula 1 and Formula 2, the (A) n motif represents an amino acid sequence consisting of 4 to 27 amino acid residues and the number of alanine residues with respect to the total number of amino acid residues in the (A) n motif is 80% or more, REP represents an amino acid sequence consisting of 10 to 200 amino acid residues, m represents an integer of 10 to 300, the plurality of (A) n motifs may be the same amino acid sequence or different amino acid sequences, and a plurality of REPs may be the same amino acid sequence or different amino acid sequences.

11. An expression vector comprising: the nucleic acid sequence according to any of one of claims 8-10 , and one or more regulatory sequences operably linked thereto.

12. A host transformed with the expression vector according to claim 11 .

13. The host according to claim 12 , which is a prokaryote.

14. The host according to claim 12 , which is a eukaryote.

15. An artificially modified fibroin composition comprising the modified fibroin according to claim 1 .

16. The artificially modified fibroin composition according to claim 15 , which is a protein powder.

17. The artificially modified fibroin composition according to claim 15 , which is a doping liquid.

18. The artificially modified fibroin composition according to claim 15 , which is a fiber.

19. The artificially modified fibroin composition according to claim 15 , which is a film.

20. A method for producing a modified fibroin, the method comprising

a step in which a host transformed with an expression vector including a nucleic acid sequence encoding a modified fibroin and one or a plurality of regulatory sequences operably linked to the nucleic acid sequence expresses the nucleic acid, wherein

the modified fibroin is the modified fibroin according to claim 1 .

21. A method for producing an artificially modified fibroin composition containing a modified fibroin, the method comprising

a step of preparing a modified fibroin, wherein

the modified fibroin is the modified fibroin according to claim 1 .

22. The production method according to claim 20 , further comprising a step of bringing the modified fibroin into contact with a carboxylic acid.

23. The production method according to claim 21 , further comprising a step of adjusting a modified fibroin solution containing the modified fibroin with a carboxylic acid.

24. A product comprising the modified fibroin according to claim 1 ,

the product being selected from the group consisting of a fiber, a yarn, a film, a foam, a grain, a nanofibril, a gel, and a resin.

Assignments (4)
RELEASE OF PATENT SECURITY INTEREST Recorded Mar 31, 2026
From: GODO KAISHA EVE
To: SPIBER INC.; SPIBER IP MANAGEMENT LLC
Reel/Frame 075350/0864 →
PATENT SECURITY AGREEMENT (US) Recorded Nov 10, 2025
From: SPIBER IP MANAGEMENT LLC
To: GODO KAISHA EVE
Reel/Frame 073567/0591 →
IN-KIND CONTRIBUTION AGREEMENT Recorded Nov 10, 2025
From: SPIBER INC.
To: SPIBER IP MANAGEMENT LLC
Reel/Frame 073567/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2021
From: MORITA, KEISUKE; ABE, YUNOSUKE; NAKAMURA, HIROYUKI; TOGASHI, SHOTA; ASAKURA, TETSUO
To: SPIBER INC.
Reel/Frame 057131/0191 →
Priority Claims (1)
JP 2019-001812 · Jan 9, 2019 · national
Continuity (1)
Related Publication 20220119463A1 · Apr 21, 2022
References Cited (37)
US 5245012A · Lombari et al. · 1993 [cited by applicant]
US 10899792B2 · Osawa · 2021 [cited by examiner]
US 20170214520A1 · Teper et al. · 2017 [cited by applicant]
US 20190135880A1 · Morita et al. · 2019 [cited by applicant]
US 20190186050A1 · Numata et al. · 2019 [cited by applicant]
US 20190233481A1 · Morita et al. · 2019 [cited by applicant]
US 20200207817A1 · Morita et al. · 2020 [cited by applicant]
CN 101018806A · 2007 [cited by applicant]
CN 101395178A · 2009 [cited by applicant]
CN 102532295A · 2012 [cited by applicant]
CN 109071619A · 2018 [cited by applicant]
EP 3859056A1 · 2021 [cited by applicant]
JP 2014502140A · 2014 [cited by applicant]
WO 1991016351A · 1991 [cited by applicant]
WO 2006008163A2 · 2006 [cited by applicant]
WO 2007078239A2 · 2007 [cited by applicant]
WO 2012050919A2 · 2012 [cited by applicant]
WO 2013065651A1 · 2013 [cited by applicant]
WO 2015042164A2 · 2015 [cited by applicant]
WO 2017222034A1 · 2017 [cited by applicant]
WO 2018034111A1 · 2018 [cited by applicant]
WO 2018164190A1 · 2018 [cited by applicant]
WO 2018221498A1 · 2018 [cited by applicant]
WO 2018235958A1 · 2018 [cited by applicant]
WO 2019022163A1 · 2019 [cited by applicant]
WO WO2019054506A1 · 2019 [cited by examiner]
WO WO2020067573A1 · 2020 [cited by examiner]
Lee et al., Mechanical behavior comparison of spider and silkworm silks using molecular dynamics at atomic scale, Phys Chem Chem Phys 18, 4814. (Year: 2016). [cited by examiner]
Narita, Kozo, “Reaction of Anhydrous Formic Acid with Proteins”, Journal of American Chemical Society, Apr. 5, 1959, pp. 1751-1756. [cited by applicant]
“Artificial synthesis spider silk protein MASP2”, Mar. 15, 2017, pp. 1-83, English Abstract. [cited by applicant]
Zhoughu, Wu, “The research of secondary structure and spinning mechanism of recombinant spider silk protein”, May 15, 2017, pp. 1-57, English Abstract. [cited by applicant]
Wang et al., “Research Progress in Spidroin Gene Recombinant Expression”, China Academic Journal Electronic Publishing House, Mar. 30, 2017, pp. 24-27, English Abstract. [cited by applicant]
Patent Cooperation Treaty, International Search Report issued in PCT/JP2020/000535, Jul. 22, 2021, pp. 1-11. [cited by applicant]
Patent Cooperation Treaty, International Preliminary Report on Patentability issued in PCT/JP2020/000535, Mar. 17, 2020, pp. 1-3. [cited by applicant]
Lazaris et al., “Spider Silk Fibers Spun from Soluble Recombinant Silk Produced in Mammalian Cells.”, Science, 2002, pp. 472-476, vol. 295(5554). [cited by applicant]
European Patent Office, Extended European Search Report issued in EP 20738473.6, Apr. 21, 2023, pp. 1-45. [cited by applicant]
Ko Jae Sang et al, “Effect of Sericin Content on the Structural Characteristics and Properties of Electro-spun Regenerated Silk”, Ffibers and Polymers, The Korean Fiber Society, Seoul, Mar. 23, 2018, pp. 507-514, XP0364… [cited by applicant]